Please login to the form below
12
Revenue 2017Bayer
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Bayer's 2013 sales performance.
Biogen takes on Lucentis, Eylea biosimilars from Samsung joint venture
Under the deal, Biogen is taking exclusive rights to Samsung Bioepis’ SB11, a biosimilar of Novartis/Roche’s Lucentis (ranibizumab), as well as SB15 which is a version of ... It has since been overtaken by rival VEGF drug Eylea, with Regeneron
Aveo’s tivozanib is knocked back by FDA once again
the TIVO-1 trial of VEGF inhibitor tivozanib – then partnered with Astellas – which compared the drug to Bayer’s VEGF drug Nexavar (sorafenib) in renal cell carcinoma (RCC).
New faces at Healthware Group and HRW
Commenting on her new role, Milburn said “from CVS and Sleepio to OneDrop and Bayer, to Happify and Sanofi, every day more and more strategic partnerships are being born between various
Roche eyes filings for Tecentriq/Avastin combo in liver cancer
plus anti-VEGF antibody Avastin (bevacizumab) or Bayer’s Nexavar (sorafenib), a standard first-line therapy for HCC.
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Featured jobs
-
Account Director, Medical Education
-
Salary TBC
- Senior Medical Writer – Leading Medical Communications Agency – ...
-
Highly Competitive Remuneration Package
- Scientific Director - Medical Education - Cheshire & London ...
-
Excellent Remuneration Package
- Senior Editor - Medical Communications - South East - Buckingham...
-
Highly competitive salary &package
- Scientific Director - Medical Communications - Berkshire
-
Excellent package on offer
- Senior / Principal Medical Writer – Medical Education - UK &...
-
Excellent Salary and Benefits on offer
- Graduate / Entry Level Opportunities – Medical Communications – ...
-
Highly Competitive Remuneration Package
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
-
Account Director
-
Salary TBC
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
-
Account Executive
-
Salary TBC
-
Account Supervisor
-
Salary TBC
- Experienced / Senior Medical Writer - MedComms - Cardiff - Wales
-
Excellent Salary and Benefits on offer
- Scientific Director - Medical Communications Agency - New York
-
Excellent Remuneration Package
-
Senior Medical Writer
-
Salary TBC
- Entry Level Editorial Assistant – Medical Education –Buckinghams...
-
Highly Competitive
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
Subscribe to our email news alerts
- FDA advisors say no to empagliflozin in type 1 diabetes
- BMS, Celgene merger should close this week after FTC okay
- AbbVie sells $30bn of bonds ahead of Allergan merger
- Nucala works in rare inflammatory disease, says GSK
- PMEA 2018 Photo Gallery - PMEA
- MSD hangs ‘for sale’ sign on French facility, shedding 207 staff
- Bayer, Merck’s high-risk heart failure drug comes good in phase 3
- Rethinking trials: the pros and cons of protocol amendments
- Using human insights to push healthcare communications forward
- RWE Blog 4: The place of real-world evidence in the market access strategy
- Don’t we all need to be able to change something?
- Antibiotic resistance: The silent pandemic
PMHub
mXm Medical Communications
mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...
Latest intelligence
- Rethinking trials: the pros and cons of protocol amendments
- Protocol amendments occur often and can be beneficial, but the steps involved can be complex...
- Using human insights to push healthcare communications forward
- This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...
- RWE Blog 4: The place of real-world evidence in the market access strategy
- The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...
Quick links
Infographics
